Hopefully This Is Clearer
ENDOSONICS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)
Three Months Six Months
Ended June 30, Ended June 30,
1997 1996 1997 1996
_______ _______ _______ ________
Total revenue $7,134 $7,101 $13,464 $12,773
Cost of sales 3,819 5,306 7,238 8,802
_______ _______ _______ ________
Gross profit 3,315 1,795 6,226 3,971
Operating expenses:
Other research, development
and clinical 910 2,232 1,926 3,845
Marketing and sales 1,029 2,139 1,935 3,694
General and administrative 861 1,806 1,690 2,662
_______ _______ _______ _______
Restructuring -- 518 -- 518
_______ _______ _______ _______
Total operating expenses 2,800 6,695 5,551 10,719
_______ _______ _______ _______
Income (loss) from operations 515 (4,382) 675 (6,230)
Equity in net loss of CVD (261) (49) (526) (49)
Other income (expense):
Interest income 497 595 1,101 1,183
Distributorship fees and
other -- (34) 3 (16)
_______ _______ _______ _______
Total other income 497 561 1,104 1,170
_______ _______ _______ _______
Net income (loss) $751 ($4,388) $1,256 ($5,627)
======= ======= ======= =======
Net income (loss) per share $0.05 ($.33) $0.08 ($.42)
======= ======= ======= =======
Shares used in the
calculation of net
income (loss) per share 15,366,510 13,448,205 15,463,308 13,271,181
========== ========== ========== ==========
CONTACT: EndoSonics
Donald Huffman, 916/368-8008
or
Morgen-Walke Associates, Inc.
Doug Sherk/John Swenson, 415/296-7383
David Sasso, Joshua Passman, 212/850-5600 |
